Purpose : Development of glaucoma neuroprotective treatment is therefore a pressing unmet medical need. We carried out an observational retrospective clinical study to analyze the synergic neuroprotective effects of forskolin, homotaurine and L-carnosine (Gangliolife®) in glaucoma worsening patients. Methods : We retrospectively recruited 25 patients with Primary Open Angle Glaucoma (POAG) who last year had a progressive worsening of visual field (Humphrey field analyzer SITA standard threshold test 24-2) and IOP < 18 mmHg. Evaluation of the P-ERG with Retimax® with the ISCEV parameters was performed. The endpoint were: - Stabilization of the visual field indices (SITA Standard 24-2, Glaucoma Staging System GSS-2) after a period of 24 months. - Amplitude increase> 2:00 uV (P50-N95 wave) in pattern electroretinogram (P-ERG) after a period of 24 months. Results : Significant MD average increase (beta 0:07, p = 0.038) was observed (costant trend see fig. 1). In the first six months, the value of MD remains fairly stable (differences 12:18, p = 0.690). At 9 months you will notice a significant increase from baseline that is maintained to 12 months and at 18 months the value of MD decrease again. The change between baseline and 24 months is of borderline significance (1.55, p = 0.058). PSD significant mean decrease (beta -0.07, p <0.001) was noted (Fig.2). Unlike the pre period in which the value of the PSD tended to increase, during the study the PSD decreases significantly already at 6 months and continues to decrease up to 18 months. At 24 months there seems to be a slight increase (but the value is still significantly lower than the baseline). PERG avarage increase (0.08 - p <0.001) was observed (Fig. 3). The increase is significant already at 6 months (+1.23, p = 0.001). The value of the P-ERG continues to grow up to 18 months. At 24 months we observed a decrease, but the value is still significantly higher than baseline. Conclusions : We showed that a combined treatment with forskolin, homotaurine, and L-carnosine affords neuroprotection in glaucoma worsening patients. Steady state in visual field parameters (MD, PSD) and significant increase of P50-N95 wave (P-ERG) were the clinic data collected. All that reported confirm the synergic neuroprotective effect on RGC survival recently observed in vivo experimental model.
Retrospective evaluation of visual fields and pattern-ERG in glaucoma worsening patients treated with forskolin, homotaurine, and L-carnosine
Gagliano C;
2016-01-01
Abstract
Purpose : Development of glaucoma neuroprotective treatment is therefore a pressing unmet medical need. We carried out an observational retrospective clinical study to analyze the synergic neuroprotective effects of forskolin, homotaurine and L-carnosine (Gangliolife®) in glaucoma worsening patients. Methods : We retrospectively recruited 25 patients with Primary Open Angle Glaucoma (POAG) who last year had a progressive worsening of visual field (Humphrey field analyzer SITA standard threshold test 24-2) and IOP < 18 mmHg. Evaluation of the P-ERG with Retimax® with the ISCEV parameters was performed. The endpoint were: - Stabilization of the visual field indices (SITA Standard 24-2, Glaucoma Staging System GSS-2) after a period of 24 months. - Amplitude increase> 2:00 uV (P50-N95 wave) in pattern electroretinogram (P-ERG) after a period of 24 months. Results : Significant MD average increase (beta 0:07, p = 0.038) was observed (costant trend see fig. 1). In the first six months, the value of MD remains fairly stable (differences 12:18, p = 0.690). At 9 months you will notice a significant increase from baseline that is maintained to 12 months and at 18 months the value of MD decrease again. The change between baseline and 24 months is of borderline significance (1.55, p = 0.058). PSD significant mean decrease (beta -0.07, p <0.001) was noted (Fig.2). Unlike the pre period in which the value of the PSD tended to increase, during the study the PSD decreases significantly already at 6 months and continues to decrease up to 18 months. At 24 months there seems to be a slight increase (but the value is still significantly lower than the baseline). PERG avarage increase (0.08 - p <0.001) was observed (Fig. 3). The increase is significant already at 6 months (+1.23, p = 0.001). The value of the P-ERG continues to grow up to 18 months. At 24 months we observed a decrease, but the value is still significantly higher than baseline. Conclusions : We showed that a combined treatment with forskolin, homotaurine, and L-carnosine affords neuroprotection in glaucoma worsening patients. Steady state in visual field parameters (MD, PSD) and significant increase of P50-N95 wave (P-ERG) were the clinic data collected. All that reported confirm the synergic neuroprotective effect on RGC survival recently observed in vivo experimental model.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
